Editas Appoints Dan Ory as Chief Medical Officer
Editas Medicine appointed Dan Ory, M.D., chief medical officer effective September 8, 2026. He will oversee clinical-development strategy and operations as EDIT-401 approaches clinical development for hyperlipidemia and will support the broader in-vivo gene-editing…
